IRIDEX Corporation (NASDAQ:IRIX) Short Interest Update

IRIDEX Corporation (NASDAQ:IRIX) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 73,137 shares, a decline of 46.9% from the January 29th total of 137,748 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 67,226 shares, the short-interest ratio is currently 1.1 days. Based on an average daily trading volume, of 67,226 shares, the short-interest ratio is currently 1.1 days. Currently, 0.5% of the company’s stock are short sold.

IRIDEX Stock Performance

IRIX traded down $0.06 during trading on Friday, hitting $1.40. 43,923 shares of the stock were exchanged, compared to its average volume of 58,321. The company has a quick ratio of 1.35, a current ratio of 1.94 and a debt-to-equity ratio of 62.29. IRIDEX has a 1-year low of $0.78 and a 1-year high of $1.65. The stock has a fifty day moving average price of $1.36 and a two-hundred day moving average price of $1.19. The firm has a market capitalization of $24.07 million, a P/E ratio of -4.67 and a beta of 0.70.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IRIX. Alliance Global Partners initiated coverage on IRIDEX in a report on Thursday, February 5th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IRIDEX in a report on Monday, December 29th. Finally, iA Financial set a $3.00 price target on shares of IRIDEX in a research note on Thursday, February 5th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Trading of IRIDEX

Several institutional investors and hedge funds have recently bought and sold shares of IRIX. Jane Street Group LLC boosted its stake in IRIDEX by 93.9% during the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 15,377 shares during the period. Susquehanna International Group LLP increased its stake in IRIDEX by 46.2% in the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 17,834 shares during the period. Thompson Davis & CO. Inc. purchased a new stake in shares of IRIDEX in the fourth quarter valued at about $32,000. Apexium Financial LP boosted its stake in shares of IRIDEX by 53.0% during the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 34,834 shares during the period. Finally, Citadel Advisors LLC boosted its stake in shares of IRIDEX by 62.7% during the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after buying an additional 42,202 shares during the period. Hedge funds and other institutional investors own 20.10% of the company’s stock.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.